Zomedica Corp. [AMEX: ZOM] gained 1.08% or 0.02 points to close at $1.87 with a heavy trading volume of 59016004 shares. The company report on February 27, 2021 that Zomedica Corp. Announces Year End 2020 Financial Results.
Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, reported consolidated financial results for the year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Robert Cohen, Zomedica’s Chief Executive Officer, commented: “While we are thankful for our substantially improved balance sheet, we continue to be good stewards of our funds by remaining efficient in our operations as we prepare for the upcoming commercial release of TRUFORMA®.”.
It opened the trading session at $1.75, the shares rose to $1.99 and dropped to $1.74, the range by which the price of stock traded the whole day. The daily chart for ZOM points out that the company has recorded 1437.83% gains over the past six months. However, it is still -3016.67% lower than its most recent low trading price.
If we look at the average trading volume of 175.81M shares, ZOM reached to a volume of 59016004 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Zomedica Corp. [ZOM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZOM shares is $1.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZOM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Zomedica Corp. is set at 0.29 The Price to Book ratio for the last quarter was 23.38, with the Price to Cash per share for the same quarter was set at 0.06.
Trading performance analysis for ZOM stock
Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.98. With this latest performance, ZOM shares gained by 106.72% in over the last four-week period, additionally plugging by 1437.83% over the last 6 months – not to mention a rise of 648.30% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 53.15, with the RSI for the last a single of trading hit 46.97, and the three-weeks RSI is set at 56.60 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 1.1413, while it was recorded at 1.9520 for the last single week of trading, and 0.3924 for the last 200 days.
Zomedica Corp. [ZOM]: A deeper dive into fundamental analysis
Return on Total Capital for ZOM is now -687.86, given the latest momentum, and Return on Invested Capital for the company is -687.85. Return on Equity for this stock declined to -687.85, with Return on Assets sitting at -387.30.
Reflecting on the efficiency of the workforce at the company, Zomedica Corp. [ZOM] managed to generate an average of -$706,573 per employee.Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 25.60 and a Current Ratio set at 25.60.
Zomedica Corp. [ZOM]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Zomedica Corp. posted -0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.02/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -50.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZOM.
An analysis of insider ownership at Zomedica Corp. [ZOM]
There are presently around $90 million, or 6.80% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 19,340,445, which is approximately 79.474% of the company’s market cap and around 4.42% of the total institutional ownership; CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC., holding 12,254,080 shares of the stock with an approximate value of $22.91 million in ZOM stocks shares; and BLACKROCK INC., currently with $15.81 million in ZOM stock with ownership of nearly New of the company’s market capitalization.
Positions in Zomedica Corp. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 23 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 20,262,520 shares. Additionally, 17 investors decreased positions by around 4,856,670 shares, while 6 investors held positions by with 22,921,707 shares. The mentioned changes placed institutional holdings at 48,040,897 shares, according to the latest SEC report filing. ZOM stock had 15 new institutional investments in for a total of 9,016,014 shares, while 10 institutional investors sold positions of 1,398,017 shares during the same period.